Latest & greatest articles for dabigatran

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on dabigatran or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on dabigatran and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for dabigatran

21. Dabigatran for thromboembolic prophylaxis in atrial fibrillation: Evidence profile

Dabigatran for thromboembolic prophylaxis in atrial fibrillation: Evidence profile

2017 DynaMed Plus

22. Anticoagulant: the "antidote" to dabigatran (Pradaxa) is insufficiently evaluated

Anticoagulant: the "antidote" to dabigatran (Pradaxa) is insufficiently evaluated Prescrire IN ENGLISH - Spotlight ''Anticoagulant: the "antidote" to dabigatran (Pradaxa°) is insufficiently evaluated'', 1 November 2016 {1} {1} {1} | | > > > Anticoagulant: the "antidote" to dabigatran (Pradaxa°) is insufficiently evaluated Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |  (...)  |  Spotlight Anticoagulant: the "antidote" to dabigatran (Pradaxa°) is insufficiently evaluated The effects of idarucizumab (Praxbind°) have not been sufficiently evaluated: its effect against the risk of bleeding is not proven. Its authorisation as an antidote should not encourage the wider use of dabigatran. When it is necessary to thin the blood with an oral anticoagulant, warfarin, a vitamin K antagonist, is the reference treatment. Dabigatran (Pradaxa°), an anticoagulant from

2016 Prescrire

23. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II Full Text available with Trip Pro

Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II Dabigatran was non-inferior to warfarin for prevention of recurrent venous thromboembolism (VTE), and dabigatran had a lower rate of bleeding compared with warfarin in two large-scale randomised trials, RE-COVER and RE-COVER II. In this study, we investigate the efficacy and safety of dabigatran versus warfarin according to the index event that qualified the patient (...) for enrollment, either symptomatic pulmonary embolism (PE) with or without deep-vein thrombosis (DVT), or DVT alone. We then analyse the anticoagulant effect of dabigatran vs warfarin on patients enrolled with PE. The pooled dataset for the efficacy analysis consisted of 2553 and 2554 patients who were randomised to dabigatran and warfarin, respectively. Recurrent VTE/VTE-related death during the study period and additional 30-day follow-up occurred in 2.7 % of all patients on dabigatran and in 2.4

2016 EvidenceUpdates Controlled trial quality: uncertain

24. Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States Full Text available with Trip Pro

Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States Limited data are available about the real-world safety of non-vitamin K antagonist oral anticoagulants (NOACs).To compare the major bleeding risk among newly anticoagulated non-valvular atrial fibrillation (NVAF) patients initiating apixaban, warfarin, dabigatran or rivaroxaban in the United States.A retrospective (...) cohort study was conducted to compare the major bleeding risk among newly anticoagulated NVAF patients initiating warfarin, apixaban, dabigatran or rivaroxaban. The study used the Truven MarketScan(®) Commercial & Medicare supplemental US database from 1 January 2013 through 31 December 2013. Major bleeding was defined as bleeding requiring hospitalisation. Cox model estimated hazard ratios (HRs) of major bleeding were adjusted for age, gender, baseline comorbidities and co-medications. Among 29 338

2016 EvidenceUpdates

25. Reversal of the anticoagulant effect of dabigatran: idarucizumab

Reversal of the anticoagulant effect of dabigatran: idarucizumab Re Rev versal of the anticoagulant effect of ersal of the anticoagulant effect of dabigatr dabigatran: idarucizumab an: idarucizumab Evidence summary Published: 24 May 2016 nice.org.uk/guidance/esnm73 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in May 2016. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA (...) or NICE websites for up- to-date information. Summary Idarucizumab is the first agent to be licensed in the UK that reverses the anticoagulant effect of a non-vitamin K antagonist oral anticoagulant (NOAC). Its action is specific against the NOAC dabigatran etexilate. In the interim analysis of an ongoing, phase III, uncontrolled, cohort study (RE-VERSE AD; n=90), treatment with a 5 g dose of idarucizumab completely reversed the anticoagulant effect of dabigatran etexilate in adults who had either

2016 National Institute for Health and Clinical Excellence - Advice

26. Dabigatran (Pradaxa) in deep vein thrombosis and pulmonary embolism

Dabigatran (Pradaxa) in deep vein thrombosis and pulmonary embolism Prescrire IN ENGLISH - Spotlight ''In the June issue of Prescrire International: Dabigatran (Pradaxa°) in deep vein thrombosis and pulmonary embolism'', 1 June 2015 {1} {1} {1} | | > > > In the June issue of Prescrire International: Dabigatran (Pradaxa°) in deep vein thrombosis and pulmonary embolism Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |  (...)  |   |   |   |   |  Spotlight In the June issue of Prescrire International: Dabigatran (Pradaxa°) in deep vein thrombosis and pulmonary embolism FREE DOWNLOAD In the New Products section of the June issue: compared with adjusted-dose warfarin, dabigatran provides no tangible advantages for patients with pulmonary embolism or deep vein thrombosis. Warfarin remains the standard drug. Full text available for free download. Summary The anticoagulant dabigatran

2015 Prescrire

27. Dabigatran (Pradaxa)

Dabigatran (Pradaxa) © 2015 Thrombosis Canada Page 1 of 4 DABIGATRAN (PRADAXA ? ) OBJECTIVE: To provide an overview of the mechanism of action, licensed indications, dosing regimens, and side- effects of dabigatran. MECHANISM OF ACTION: Dabigatran is an oral direct thrombin (factor IIa) inhibitor. By binding reversibly to the active site of thrombin, dabigatran attenuates thrombin activity and reduces fibrin formation. INDICATIONS: Dabigatran is currently licensed in Canada for the following (...) impairment (creatinine clearance [CrCl] 30 to 50 mL/min). Dabigatran is contraindicated in patients with a CrCl <30 mL/min. c) Treatment of DVT and PE: Dabigatran 150 mg BID is started after 5 to 10 days of initial treatment with a parenteral anticoagulant. There is no recommended dose adjustment in patients with moderate renal impairment (CrCl 30 to 50 mL/min). The reduced dose of 110 mg has neverbeen evaluated in a VTE treatment clinical trial. ? Dabigatran should not be used in patients with a CrCl

2015 Thrombosis Interest Group of Canada

28. Idarucizumab for the reversal of anticoagulation due to treatment with dabigatran ? first line

Idarucizumab for the reversal of anticoagulation due to treatment with dabigatran ? first line Idarucizumab for the reversal of anticoagulation due to treatment with dabigatran – first line Idarucizumab for the reversal of anticoagulation due to treatment with dabigatran – first line NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation NIHR HSC. Idarucizumab for the reversal of anticoagulation due to treatment with dabigatran – first line . Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2015 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal, Humanized; Anticoagulants; Benzimidazoless; Blood Coagulation; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Thromboembolism Language Published English Country of organisation England English

2015 Health Technology Assessment (HTA) Database.

29. Praxbind (idarucizumab) - For use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa?s blood-thinning effects

Praxbind (idarucizumab) - For use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa?s blood-thinning effects Praxbind (idarucizumab) U.S. Department of Health and Human Services Search FDA Submit search Praxbind (idarucizumab) Vraylar (Cariprazine) Company: Boehringer Ingelheim Pharmaceuticals Application No.: 761025 Orig1 Approval Date: October 16, 2015 Persons with disabilities having problems accessing

2015 FDA - Drug Approval Package

30. Bleeding events with dabigatran or warfarin in patients with venous thromboembolism (Abstract)

Bleeding events with dabigatran or warfarin in patients with venous thromboembolism Dabigatran was as effective as warfarin for the acute treatment of venous thromboembolism in the RE-COVER and RE-COVER II trials. We compared the incidence of bleeding with dabigatran versus warfarin in pooled data from these studies. The localisation, bleeding severity, and the impact of key factors on the incidence of bleeding, were compared between the dabigatran and warfarin treatment group. Altogether, 2553 (...) patients received dabigatran and 2554 warfarin, each for a mean of 164 days. The incidence of any bleeding event was significantly lower with dabigatran (hazard ratio [HR] 0.70; 95% confidence interval [CI], 0.61-0.79), as was the incidence of the composite of MBEs and clinically relevant non-major bleeding events (HR 0.62; 95% CI, 0.50-0.76). The incidence of major bleeding events (MBEs) was also significantly lower with dabigatran in the double-dummy phase (HR, 0.60; 95%CI, 0.36-0.99

2015 EvidenceUpdates Controlled trial quality: uncertain

31. Cohort study: Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin

Cohort study: Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin | BMJ Evidence (...) OR managers of institutional accounts Username * Password * your user name or password? You are here Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin Article Text Aetiology/Harm Cohort study Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin

2015 Evidence-Based Medicine

32. Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism Dabigatr Dabigatran ete an etexilate for the treatment xilate for the treatment and secondary pre and secondary prev vention of deep v ention of deep vein ein thrombosis and/or pulmonary embolism thrombosis and/or pulmonary embolism T echnology appraisal guidance Published: 17 December 2014 nice.org.uk/guidance/ta327 © NICE 2018. All rights reserved. Subject to Notice of rights (...) . They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis

2015 National Institute for Health and Clinical Excellence - Technology Appraisals

33. Dabigatran (Pradaxa): life-threatening bleeding

Dabigatran (Pradaxa): life-threatening bleeding Prescrire IN ENGLISH - Spotlight: Archive ''Dabigatran (Pradaxa°): life-threatening bleeding'', 1 February 2013 {1} {1} {1} | | > > > Dabigatran (Pradaxa°): life-threatening bleeding Spotlight: Archives Every month, the subjects in Prescrire’s Spotlight. 2013 :  |   |  Spotlight Archives Dabigatran (Pradaxa°): life-threatening bleeding FEATURED REVIEW Dabigatran is an oral anticoagulant that inhibits thrombin but not vitamin K (...) . Pharmacovigilance studies have identified several situations in which patients have an increased risk of serious bleeding with dabigatran. Dabigatran should be reserved for patients at high risk of thrombosis in whom antivitamin K therapy poses difficult problems. Full review (3 pages) available for download by subscribers. Abstract Dabigatran (Pradaxa°) is an oral anticoagulant that inhibits thrombin but not vitamin K. In mid-2012, there was no commercial test to monitor its anticoagulant effect, nor

2014 Prescrire

34. Bleeding with dabigatran, rivaroxaban, apixaban: no antidote, and little clinical experience

Bleeding with dabigatran, rivaroxaban, apixaban: no antidote, and little clinical experience Prescrire IN ENGLISH - Spotlight ''Bleeding with dabigatran, rivaroxaban, apixaban: no antidote, and little clinical experience '', 1 June 2013 {1} {1} {1} | | > > > Bleeding with dabigatran, rivaroxaban, apixaban: no antidote, and little clinical experience Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |    (...) |   |   |   |  Spotlight Bleeding with dabigatran, rivaroxaban, apixaban: no antidote, and little clinical experience FEATURED REVIEW Dabigatran, rivaroxaban and apixaban are oral anticoagulants used to prevent or treat thrombosis. Difficulties in the management of bleeding weigh heavily in the balance of potential harm versus potential benefit of these drugs. Full review (5 pages) available for download by subscribers. Abstract Dabigatran, rivaroxaban and apixaban

2014 Prescrire

35. Randomised controlled trial: Evidence suggests dabigatran is an effective and safe treatment for patients with VTE requiring early parenteral therapy

Randomised controlled trial: Evidence suggests dabigatran is an effective and safe treatment for patients with VTE requiring early parenteral therapy Evidence suggests dabigatran is an effective and safe treatment for patients with VTE requiring early parenteral therapy | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies (...) , please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Evidence suggests dabigatran is an effective and safe treatment for patients with VTE requiring early parenteral

2014 Evidence-Based Medicine

36. [Overview of dabigatran usage among people insured by the public prescription drug insurance plan]

[Overview of dabigatran usage among people insured by the public prescription drug insurance plan] Portrait de l'usage du dabigatran chez les personnes assurées par le régime public d'assurance médicaments [Overview of dabigatran usage among people insured by the public prescription drug insurance plan] Portrait de l'usage du dabigatran chez les personnes assurées par le régime public d'assurance médicaments [Overview of dabigatran usage among people insured by the public prescription drug (...) insurance plan] Tremblay E Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Tremblay E. Portrait de l'usage du dabigatran chez les personnes assurées par le régime public d'assurance médicaments . [Overview of dabigatran usage among people insured by the public prescription drug insurance plan] . Quebec: Institut national d'excellence en sante et

2014 Health Technology Assessment (HTA) Database.

37. Dabigatran and Mechanical Heart Valves - Not as Easy as We Hoped. Full Text available with Trip Pro

Dabigatran and Mechanical Heart Valves - Not as Easy as We Hoped. 23991659 2013 10 17 2018 12 02 1533-4406 369 13 2013 Sep 26 The New England journal of medicine N. Engl. J. Med. Dabigatran and mechanical heart valves--not as easy as we hoped. 1264-6 10.1056/NEJMe1310399 Hylek Elaine M EM eng Editorial Comment 2013 08 31 United States N Engl J Med 0255562 0028-4793 0 Anticoagulants 0 Benzimidazoles 11P2JDE17B beta-Alanine 5Q7ZVV76EI Warfarin I0VM4M70GC Dabigatran AIM IM N Engl J Med. 2013 Sep (...) 26;369(13):1206-14 23991661 Anticoagulants administration & dosage Atrial Fibrillation drug therapy Benzimidazoles administration & dosage Dabigatran Female Heart Valve Prosthesis Humans Male Stroke prevention & control Thromboembolism prevention & control Warfarin administration & dosage beta-Alanine administration & dosage analogs & derivatives 2013 9 3 6 0 2013 9 3 6 0 2013 10 18 6 0 ppublish 23991659 10.1056/NEJMe1310399

2013 NEJM

38. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation Full Text available with Trip Pro

Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation Harrington AR, Armstrong EP, Nolan PE, Malone DC Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) . Interventions The four interventions were warfarin, apixaban 5mg twice daily, dabigatran 150mg twice daily, and rivaroxaban 20mg once daily. Warfarin dose was assumed to be adjusted to achieve the patient's target international normalised ratio (INR). Location/setting USA/in-patient and out-patient care. Methods Analytical approach: A Markov model, with one-month cycles, combined the published data. The time horizon was 30 years and the authors stated that the perspective was societal. Effectiveness data

2013 NHS Economic Evaluation Database.

39. Dabigatran etexilate - Atrial fibrillation prevention of stroke and systemic embolism

Dabigatran etexilate - Atrial fibrillation prevention of stroke and systemic embolism Common Drug Review CDEC Meeting — June 19, 2013 Notice of CDEC Final Recommendation — July 18, 2013 Page 1 of 6 © 2013 CADTH CDEC FINAL RECOMMENDATION DABIGATRAN ETEXILATE (Pradaxa — Boehringer Ingelheim [Canada] Ltd.) Indication: Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that dabigatran be listed (...) for the prevention of stroke and systemic embolism in patients with atrial fibrillation who meet all of the following clinical criteria: Clinical Criteria: 1. Patients with a CHADS2 score = 1. 2. Patients who are unable to readily achieve adequate anticoagulation with warfarin. Reasons for the Recommendation: 1. In one large open-label randomized controlled trial (RCT) (RE-LY), the annual incidence of stroke or systemic embolism was statistically significantly less with dabigatran 150 mg twice daily (1.11

2013 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

40. Ischemic stroke in an obese patient receiving dabigatran. (Abstract)

Ischemic stroke in an obese patient receiving dabigatran. 23782198 2013 06 28 2015 11 19 1533-4406 368 25 2013 Jun 20 The New England journal of medicine N. Engl. J. Med. Ischemic stroke in an obese patient receiving dabigatran. 2440-2 10.1056/NEJMc1215900 Breuer Lorenz L Ringwald Jürgen J Schwab Stefan S Köhrmann Martin M eng Case Reports Letter United States N Engl J Med 0255562 0028-4793 0 Antithrombins 0 Benzimidazoles 0 Proton Pump Inhibitors 11P2JDE17B beta-Alanine I0VM4M70GC Dabigatran (...) AIM IM Antithrombins adverse effects pharmacokinetics Benzimidazoles adverse effects pharmacokinetics Dabigatran Humans Male Middle Aged Obesity complications Proton Pump Inhibitors therapeutic use Stroke chemically induced beta-Alanine adverse effects analogs & derivatives pharmacokinetics 2013 6 21 6 0 2013 6 21 6 0 2013 7 3 6 0 ppublish 23782198 10.1056/NEJMc1215900

2013 NEJM